Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness

BACKGROUND: Two new agents have recently been licensed for use in the treatment of metastatic renal cell carcinoma (RCC) in Europe. This paper aims to systematically review the evidence from all available randomised clinical trials of sunitinib and bevacizumab (in combination with interferon-α (IFN-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Thompson Coon, J S, Liu, Z, Hoyle, M, Rogers, G, Green, C, Moxham, T, Welch, K, Stein, K
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2009
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2720220/
https://ncbi.nlm.nih.gov/pubmed/19568242
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605167
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados